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ABBREVIATIONS AND CONCEPTS 
ACTB  Actin beta  
AMPK  Adenosine monophosphate-activated protein kinase  
AT Adipose tissue 
CG 
Eff 
Cultivated high-yielding pasture group 
PCR efficiency 
EMS Equine metabolic syndrome  
GAP GTPase-activating protein 
GLUT4 Glucose transporter type 4 
GTP Guanosine triphosphate 
GUSB 
ICG 
Glucuronidase beta 
Internal control gene 
IR Insulin resistance 
LEP  Leptin  
MCP-1  Monocyte chemoattractant protein-1 
MRPL39 Mitochondrial ribosomal protein L39 
mTOR Mechanistic target of rapamycin 
mTORC1  Mechanistic target of rapamycin complex 1 
NEFA 
NG 
Non-esterified fatty acids 
Semi-natural grassland group 
PRAS40 Proline-rich Akt substrate 40 kDa 
qPCR Quantitative  polymerase chain reaction 
RBP4 Retinol binding plasma protein 4  
Rheb Ras homolog enriched in brain 
SAT Subcutaneous adipose tissue 
SREBF1 Sterol regulatory element binding transcription factor 1  
SREBF2 Sterol regulatory element binding transcription factor 2  
TBC  Tre-2/Bub2/Cdc16 
TBC1D7  TBC domain family member 7 
TSC1  Tuberous sclerosis 1  
TSC2 Tuberous sclerosis 2  
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1 INTRODUCTION  
 
Nowadays obesity has reached epidemic proportions worldwide due to changes in human 
lifestyle (Catenacci et al. 2009). Diet may play an important role in eliciting obesity by 
affecting insulin dynamics (Hoffman et al. 2003, Isganaitis & Lustig 2005). Increased 
adiposity is a major cause of insulin resistance (IR), dyslipidemia, hyperglycemia, and 
hypertension (Kahn & Flier 2000, Spiegelman & Flier 2001). The prevalence of obesity 
also has been risen dramatically in companion animals as well as in domestic horses and 
ponies (Giles et al. 2014).  It has been reported that obesity is an increasing common 
disease and welfare issue in equines in developed countries (Thatcher et al. 2008, Wyse et 
al. 2008).  
 
Equine metabolic syndrome (EMS) is an endocrinopathic disease of horses and ponies 
characterized by abnormal regional obesity, hyperinsulinemia and insulin resistance, altered 
reproductive cycling, laminitis, dyslipidemia and hyperleptinemia (Vick et al. 2008, Frank 
et al. 2010b).  In horses, obesity is known as a key factor leading to an increased risk of 
insulin resistance, laminitis and metabolic syndrome (Hoffman et al. 2003, Treiber et al. 
2006, Geor 2008). Obesity has been reported to associate with insulin resistance through 
inflammatory response and increased plasma lipid concentrations in equine and companion 
animals (Frank et al. 2006, Vick et al. 2007, Radin et al. 2009). However, the molecular 
mechanisms from obesity leading up to insulin resistance, laminitis or EMS have to yet 
been explained in detail.  
 
mTORC1 genes and insulin-pathway genes may contribute to increased IR (Lamming et al. 
2012). It is suggested that mTORC1 activation induces lipogenesis in adipose tissues 
(Ricoult & Manning 2013). In human and laboratory animal studies, it has been shown that 
certain pathways related to cytokines and adipokines are associated with obesity, insulin 
resistance and inflammation (Guiherme et al. 2008). In equidae, several studies underlined 
the role of adipose tissue in regulation of metabolism and homeostasis by various cytokines 
(Carter 2008, Burns et al. 2010, Frank et al. 2010a, Ungru et al. 2012). However, the 
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molecular mechanisms that link those cytokines, obesity and insulin resistance remain 
incompletely understood, which is of importance for further investigation.  
 
 
2 LITERATURE REVIEW 
 
2.1 Background of mTORC1 
 
Rapamycin is a macrolide antibiotic produced by Streptomyces hygroscopicus. It was first 
extracted for its antifungal activity against Candida albicans (Vézina et al. 1975). The 
mechanistic target of rapamycin (mTOR, formerly known as mammalian TOR) is an 
atypical serine/threonine protein kinase which belongs to the phosphoinositide 3-kinase-
related kinase family. TOR1 and TOR2 were identified in a screen of budding yeast 
Saccharomyces cerevisiae, and their role as transmitters of the toxic effect of rapamycin 
was discovered in early 1990s (Kunz et al. 1993, Cafferkey et al. 1993, Helliwell et al. 
1994). Shortly after, mTOR was cloned and studied as target of rapamycin (Brown et al. 
1994, Sabatini et al. 1994, Chiu et al. 1994, Sabers et al. 1995).   
 
The mechanistic target of rapamycin complex 1 (mTORC1) is one of the distinct 
complexes that formed with mTOR and several protein components. It has been recently 
discovered that mTORC1 includes the catalytic mTOR subunit and five other known 
protein components (Dibble et al. 2013).  
 
It was claimed that the molecular function of regulatory-associated protein of mammalian 
target of rapamycin (raptor) is to function as a binding partner of TOR (Hara et al., 2002). It 
was also argued that mTOR signals to the cell cycle progression and proliferation by 
interacting with raptor (Kim et al., 2002). Target of rapamycin complex subunit LST8, as 
known as mammalian lethal with SEC 13 protein 8 (mLST8), was reported as a positive 
regulator of the rapamycin sensitive pathway (Kim et al. 2003). Proline-rich Akt substrate 
40 kDa (PRAS40) was found an insulin-regulated inhibitor of the mTORC1 kinase activity 
(Sancak et al. 2007, Wang et al. 2007). PRAS40 was proposed to regulate apoptosis by 
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interacting with mTOR (Thedieck et al. 2007). DEP domain containing mTOR-interacting 
protein (DEPTOR) was reported as a mTOR inhibitor (Peterson et al. 2009).  Kaizuka et al. 
(2010) discussed the critical importance of Tti1/Tel2 complex as its role in regulating the 
stability of mTORC1. 
 
2.2 Upstream and downstream of mTORC1 signaling pathway  
 
From upstream, mTORC1 is activated by insulin and most other growth factors through 
either receptor tyrosine kinases or G-protein-coupled receptors at the cell surface (Loewith 
& Hall 2011). mTORC is regulated directly through the GTP-binding status of the Ras 
homolog enriched in brain (Rheb) (Huang & Manning 2008). The tuberous sclerosis 
complex 1/2 (TSC1/2, Tuberin and Hamartin) negatively regulate mTORC1 by acting as 
GTPase-activating protein (GAP) of Rheb (Tee et al. 2003). Nutritional signals such as 
glucose, amino acids and oxygen, or insulin, cytokines, growth factors and energy 
metabolism affect the GAP ability of the TSC-TBC complex through adenosine 
monophosphate-activated protein kinase (AMPK) and v-Akt murine thymoma viral 
oncogene (Akt) (Dibble et al. 2012). The phosphorylation of TSC2 by Akt can inhibit the 
TSC-TBC complex, thereby activating Rheb and mTORC1 kinase activity (Inoki et al. 
2002). The mTORC1 signaling can also be activated without insulin by expression of 
constitutively active Akt or lack of either TSC1 or TSC2, meanwhile, it stimulates 
expression of SREBP1 and SREBP2 targets (Porstmann et al. 2008, Düvel et al. 2010). 
Generally, mTORC1 signaling plays a multifunctional role in controlling mammalian lipid 
metabolism including lipid synthesis, storage and lipolysis, and adipocyte differentiation 
(Figure 1).  
 
Activation of mTORC1 promotes biomass increase for cell growth and proliferation 
(Howell & Manning 2011, Laplante & Sabatini 2012). Through various downstream 
mechanisms, mTORC1 regulates lipid metabolism by promoting lipid synthesis and 
inhibiting lipid release, promoting the production of energy and reducing equivalents 
(Yecies & Manning 2011, Inoki et al. 2012, Ricoult & Manning 2013).  
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Figure 1. Upstream activation factors of mTORC1 and its downstream target regulation. Adapted 
from Ricoult & Manning (2013).  
 
 
The activation of mTORC1 signaling stimulates lipogenesis through SREBP1 and SREBP2 
which are major transcriptional factors (Porstmann et al. 2008, Düvel et al. 2010). Genetic 
models have suggested that mTORC1 plays a vital role in terminal adipocyte differentiation 
and adipogenesis (Zhang et al. 2009). Meanwhile, several studies suggested that mTORC1 
signaling promotes fatty acids storage by inhibiting lipolysis (Morrisett et al. 2002, Zhang 
et al. 2009, Chakrabarti et al. 2010, Soliman et al. 2010). However, the molecular 
mechanisms by which mTORC1 stimulates adipocytes differentiation and regulates 
lipolysis have not yet been clarified.  
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It is claimed that mTORC1 may contribute to various metabolic diseases such as obesity, 
insulin resistance, diabetes and cancer via its important role in integrating cellular signals 
and regulating lipid synthesis, storage and transportation (Ricoult & Manning 2013).  In 
human and laboratory animals studies, the role and molecular mechanisms of mTORC1 
have been well established, while in horses the knowledge remains obscure.  
 
2.3 The expression of adipokine genes in metabolic diseases  
 
Retinol binding protein 4 (RBP4) is an adipokine secreted by adipocytes (Yang et al. 2005). 
In mice and human study, RBP4 contributes to insulin resistance in obesity and type-2 
diabetes (Yang et al. 2005, Graham et al. 2006).  Increased serum RBP4 levels were 
observed in humans with insulin-resistant states such as obesity, type-2 diabetes (Graham et 
al. 2006). Higher blood levels of RBP4 were detected in adiposity of type-2 diabetes 
(Klöting et al. 2007, Lee et al. 2007). It was also reported that down-regulation of GLUT4 
can cause insulin resistance and increase the risk of developing diabetes (Abel, et al. 2001). 
Increased levels of serum RBP4 were detected in adipose-specific GLUT4 knockout 
(adipose-GLUT4 -/-) mice (Yang et al. 2005). However, in an equine study, RBP4 
expression was claimed closely linked with adiposity, independent of other obesity factors 
such as insulin sensitivity (Ungru et al. 2012). 
 
Leptin (LEP) regulates appetite, adipogenesis and energy homeostasis (Ingvartsen & 
Boisclair 2001). Previous equine study has reported that LEP is as an important endocrine 
signal of nutritional status and adipose tissue mass in the horse (Houseknecht et al. 1998). 
The plasma LEP concentration was positively correlated with adipose tissue mass, and 
strongly correlated with degree of insulin resistance (Buff et al. 2002, Kearns et al. 2006, 
Van Weyanberg et al. 2007). 
 
MCP1 was reported to contribute to macrophage infiltration into adipose tissue and insulin 
resistance in obesity (Kanda et al. 2006). In human studies, the mRNA expression of MCP1 
was up-regulated in adipose tissue in obese subjects (Christiansen et al. 2005). Increased 
circulating level of MCP1 was also observed in obese humans (Kim et al. 2006). MCP1 
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levels were higher in diabetic than in non-diabetic Afro-Caribbean subjects (Ezenwaka et al. 
2009). Similarly, in mice studies, it was reported that elevated circulating concentration of 
MCP1 can lead to systemic insulin resistance (Tateya et al. 2010). However, Burns et al. 
(2010) did not find statistically significant differences have in mRNA expression of anti-
inflammatory adipokine such as MCP1 between insulin resistant and insulin sensitive 
groups in obese horses, while in another recent study, a higher mRNA expression of MCP1 
was detected in overweight group compared to normal weight group in Finnhorses (Selim 
et al. 2013). 
 
3 RESEARCH OBJECTIVES 
 
The objectives of this MSc thesis study were as follows: The first objective was to find and 
validate internal control genes for quantitative PCR method for adipose tissues in Finnhorse 
mares. DNA sequences for both control and candidate genes were analysed, primers were 
designed and tested for the utilization in this experiment. The second aim was to quantitate 
the expression of mTORC1 and insulin-pathway associated genes after pasture season in 
two different treatment groups of Finnhorse mares and compare gene expression 
differences between treatment groups. Treatments aimed to analyse if pasture-associated 
energy feeding difference have effect on adiposity and thus, on the gene expression of 
adipose tissue genes in Finnhorse mares. In addition, gene expression differences were 
compared between two different adipose tissues (neck and tailhead adipose tissues).   
 
The hypotheses were that pasture-associated high energy feeding would result in 
accumulation of adiposity, which will lead to altered expression of mTORC1 and insulin-
pathway genes in subcutaneous adipose tissue.  
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4 MATERIALS AND METHODS 
 
4.1 Animals and experimental design  
 
The experimental procedures followed the protocols approved by the National Animal 
Ethics Committee in Finland. Twenty-two mares were selected in to the study. Mares were 
equally divided into eleven equal pairs according to their pedigree, medication and 
reproductive history, age, diet, weight and body condition. The two mares of each group 
were randomly selected to graze either on cultivated high-yielding pasture (CG), or semi-
natural grassland (NG) from the end of May to the beginning of September at MTT 
Agrifood Research Finland (currently Natural Resources Institute Finland (LUKE)) in 
Ypäjä. Eight pairs of mares were studied for gene expression profiling (Figure 2).  
 
 
 
 
 
Figure 2. Finnhorse mares at the semi-nature grassland (NG) in Ypäjä (Photo: Kari Elo). 
12 
 
 
 
 
4.2 Adipose tissue collection  
 
Neck and tailhead subcutaneous adipose tissue (SAT) samples were collected from two 
groups of Finnhorse mares before and after pasture season for gene expression profiling. A 
detailed description of collection of tissue samples is given in Selim et al (2015).  Tissues 
were stored at -80 °C. 
 
4.3 RNA extraction and cDNA synthesis 
 
Total RNA of neck and tailhead SAT samples were extracted and purified using RNeasy 
Lipid Tissue Mini Kit (Qiagen GmbH, Hilden, Germany). Approximately 50 mm3 (about 
55 - 65 mg) of SAT was cut from stored sample. Then the tissue was placed into a 5 ml 
tube on ice for disruption and homogenization with 1 ml QIAzol Lysis Reagent using the 
TissueRuptor for 30 seconds. After 5 min incubation at room temperature, 200 µl 
chloroform was added in to the tube for subsequent phase separation. 
 
The tube was shaken vigorously for 15 seconds and then incubated at room temperature for 
2-3 min before centrifugation at 12000 g for 15 min at 4 °C. The upper, colorless, aqueous 
phase (approximately 600 µl) was transferred to a new tube with addition of 1 volume (500 
µl- 600 µl) of 70% ethanol and vortexed. Then the sample was transferred to RNeasy 
column in 2 ml tube for centrifugation at 8000 g for 15 seconds, after the centrifugation the 
flow-through was discarded. Then, 700 µl of buffer BW1 was added to the RNeasy spin 
column to wash the column membrane with centrifugation at 8000 g for 15 seconds. Then 
the spin column was carefully removed from the collection tube to avoid contacting the 
flow-through. The membrane was washed twice (15 seconds and 2 min, respectively) with 
500 µl of buffer RPE and centrifugation at 8000 g. The spin column was centrifuged at 
8000 g for 1 min in a new 2 ml collection tube to eliminate any possible carryover of buffer 
and residual flow-through. The spin column was placed in a new 1.5 ml collection tube to 
elute the total RNA, the membrane was eluted by 30 µl of RNase-free water and 
centrifuged at 8000 g for 1 min. Then, 3 µl of each extracted total RNA sample was taken 
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to 0.2 ml collection tube for quality verification. All of the samples were then stored in -
80 °C until further use. One set of SAT samples (horse no.9, Sailori) from CG group was 
missing for RNA extraction, thus 15 animal samples (8 from NG group and 7 from CG 
group) were studied in the following steps.  
 
The total RNA quality was verified prior to qPCR experiments. RNA concentration and 
RNA integrity number (RIN) were measured using Agilent Bioanalyzer 2100 chip 
electrophoresis system and using Agilent RNA 6000 Nano Kit (Agilent Technologies, 
Santa Clara, CA, USA).  
 
The RNA 6000 dye concentrate was equilibrated at room temperature for 30 min while 
preparing the gel. The gel was prepared by centrifuging 550 µl of RNA 6000 Nano gel 
matrix in a spin filter at 1500 g for 10 min at room temperature. Then, 65 µl of filtered gel 
was pipetted into a 0.5 ml RNase-free microfuge tubes. After vortexing for 10 seconds, 1 µl 
of concentrate dye was added into 65 µl of filtered gel. The tube was vortexed and then 
centrifuged at 13000 g for 10 min at room temperature. The RNA 6000 Nano chip priming 
station was set up in position C before loading the gel-dye mix. A new chip was placed on 
the chip priming station, 9 µl of gel-dye mix was pipetted into the well with mark G. The 
plunger was positioned at 1 ml and then pressed until held by the clip, and the clip was 
released after exactly 30 seconds. The plunger was slowly pulled back to 1 ml position after 
5 seconds of waiting. Then 9 µl of gel-dye mix was pipetted into the wells marked G. After 
this, 5 µl of RNA 6000 Nano marker was pipetted into all 12 sample wells and into the 
ladder well. All RNA samples and RNA ladder was denatured by heating for 2 min at 
70 °C and then kept on ice until further use. Then, 1 µl of prepared ladder was pipetted into 
well with ladder marker and 1 µl of prepared RNA samples were pipetted separately into 
each of 12 sample wells. When applicable, 1 µl of marker was added into unused sample 
well(s). The chip was placed horizontally in the IKA vortexer adapter and vortexed at 2400 
rpm for 1 min before running in the Agilent 2100 Bioanalyzer. The running was started 
within 5 minutes from the end of vortexing. 
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Synthesis of cDNA was completed with Anchored-Oligo (dT) 18 primer using Transcriptor 
First Strand cDNA Synthesis Kit (Roche Diagnostics GmbH, Mannheim, Germany). All 
reagents were kept on ice while setting up the reactions. The template-primer mix was 
made by mixing 12 µl of each total RNA sample with 1 µl of Anchored-Oligo (dT)18 
primer (50 pmol/ µl) in a sterile, nuclease-free, thin-walled PCR tube. All the template-
primer mixtures were denatured by heating for 10 min at 65 °C and then kept on ice until 
further steps. The master mix was prepared for 35 reactions by pipetting 140 µl of 
Transcriptor Reverse Transcriptase Reaction Buffer, 17.5 µl of Protector RNase Inhibitor 
(40 U/ µl), 70 µl of Deoxynucleotide Mix, 17.5 µl of Transcriptor Reverse Transcriptase 
(20 U/ µl). Then, 7 µl of the master mix was added to each sample’s template-primer tube 
to form a total of 20 µl mixture for reaction. After brief centrifugation, the tube was placed 
in a thermal block with a heated lid, then incubated for 30 min at 55 °C and 5 min at 85 °C 
for Transcriptor Reverse Transcriptase inactivation. The reaction was stopped at 4 °C. 
Synthesized cDNA samples were stored at -20 °C until further use for Real-Time PCR. 
 
4.4 Primer design 
 
Primer sequences and lengths for PCR products of selected genes were designed using the 
online Primer3 software program (Rozen & Skaletzky, 2000). Main criteria used in primer 
design were the length of PCR product (accepted range from 100 bp to 250 bp), the nearest 
neighbor temperature (same annealing temperature (60 °C) for all primer pairs) and 
absence of sequence-based hybridization problems. Exon-exon junctions were included in 
primer sequences of selected genes. The uniqueness of primer sequences was determined 
using NCBI database and BLASTN tool.  
 
Primers were designed for six internal control genes (ICG)(Table 1). The selected internal 
control genes were actin beta (ACTB), glucuronidase beta (GUSB), mitochondrial 
ribosomal protein L39 (MRPL39). The mRNA abundances of ACTB, GUSB and MRPL39 
were evaluated together with candidate genes through different groups and adipose tissues. 
Then, the expression stabilities of these three genes were tested with NormFinder software 
(Andersen et al. 2004).  
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Table 1. Primer sequences (5’-3’) of internal control genes, GenBank accession numbers and 
lengths of PCR products. 
 
Gene Sequence (5’-3’) GenBank  Length (bp) 
ACTB For.TGACCCAGATCATGTTTGAGACC NM_001081838 139 
Rev.ATGGGCACAGTGTGGGTGA  
GUSB For.GCTGACATCCGAGGGAAGG XM_001493514 148 
Rev.CCACAATCCCATAGCGGTCA  
MRPL39 For.CCGGCTGGAGATTTATAGCA 
Rev.CACTCAAATGCATGGCACA 
XM_001496687 225 
GAPDH For. ACCATCTTCCAGGAGCGAGATC 
Rev.CCTTCTCCAAGGTAGTGAAGACACC 
NM_001163586 
 
104 
HSP90AB1 For. AGCATTTATGGAGGCTCTTCAGGC NM_001081938  107 
Rev.TGATCACAACCACCTTCTCTGCC 
RPS2 For. CCGAGAAAACACCAAATGGCGG XM_001497974  110 
Rev.CCACTGCCGAAGCCTCCG 
    
 
 
 
Candidate genes were mechanistic target of rapamycin (MTOR), sterol regulatory element 
binding transcription factor 1 (SREBF1), sterol regulatory element binding transcription 
factor 2 (SREBF2), TBC1 domain family member 7 (TBC1D7), leptin (LEP), Glucose 
transporter type 4 (GLUT4), monocyte chemoattractant protein-1 (MCP-1), retinol binding 
plasma protein 4 (RBP4), tuberous sclerosis 1 (TSC1), tuberous sclerosis 2 (TSC2) (Table 
2). 
 
16 
 
 
 
 
 
 
 
 
 
Table 2. Primer sequences (5’-3’) of candidate genes, GenBank accession numbers, lengths of PCR 
products and mean amplification efficiencies (Eff). 
 
Gene Sequence (5’-3’) GenBank Length (bp) Eff 
MTOR For.GGAGAGAGGCTATCCGTGTGTT XM_001492351 111 1,94 
 Rev.ACAGGCTGACAGCAGAAGCA    
SREBF1 For.GGCCTTTACAGACCCTGGTG XM_001918214 149 1,93 
 Rev.GTGGGCTGTGCGCTTCTC    
SREBF2 For.CAGGTTCTGGGGGCTGGT XM_005606691 146 1,94 
 Rev.GAAGGTGACTGAGGAGCGTGA    
TBC1D7 For.CCAGTTTACAGAGGGTTTGGGATA XM_001492275 128 1,91 
 Rev.TGTTATCTTCTCGGCACTGTTCA    
LEP For. CACACGCAGTCAGTCTCCTC NM_001163980 176 1,94 
 Rev.CGGAGGTTCTCCAGGTCAT    
GLUT4 For.GCCCCACAGAAGGTGATTGAA NM_001081866 200 1,91 
 Rev.CAGCATTGCCCTTTTCCTTCC    
MCP-1 For.GGCTCAGCCAGATGCAATTA NM_001081931 141 1,92 
 Rev.ATGGTCTTGAAGTTGGGACACT    
RBP4 For.TGATCTCTCACAACGGTTATTG NM_001081951 152 1,92 
 Rev.GGAGAAGAGAGGGCCAAACT    
TSC1 For.CGCAGAATAGCTATGGGAGTGC XM_001498348 108 1,95 
 Rev.GTGTCGGTGGGGAACTCAGA    
TSC2 For.GGAAGAAGAACTGGCTGAGTTTG XM_005599067 131 1,94 
 Rev.GGACCATCGATGCGATGTATT    
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4.5 Quantitative Real-Time RT-PCR  
 
Quantitative PCR (qPCR) reactions were prepared using LightCycler 480 SYBR Green I 
Master kit (Roche Diagnostics GmbH, Mannheim, Germany). The volume in qPCR 
reaction was 10 µl (2.5 µl of cDNA and 7.5 µl of master-mix), and each sample was run in 
triplicate. All the samples and reagents were kept on ice while setting up the reaction. Each 
cDNA sample was diluted 1:4 to 80 µl (20 µl cDNA diluted into 60 µl of Dnase/Rnase free 
water) for 24 reactions on 96-well plate.  
 
The final concentration of primers in qPCR was 5 pmol/ µl/each; therefore, 65 µl of 
forward primer (100 pmol/ µl) and reverse primer (100 pmol/ µl) were mixed to get 50 
pmol/ µl primer-mix dilution. The master-mix was prepared by mixing 64 µl of primer-mix, 
96 µl of Dnase/Rnase free water and 320 µl of Roche’s 2x master-mix, and then the 
solution was divided  into 8 wells on 96-well plate. The plates of master-mix and diluted 
cDNA were centrifuged at 1500 g for 2 min. PCRs were pipetted into optical 384-well 
plates using epMotion 5075 pipetting robot (Eppendorf AG, Hamburg, Germany), and then 
centrifuged at 1500 g for 2 min before incubation for 1 hour at 4 °C.  In this study, five sets 
of 384-well plates were prepared for 3 internal control genes and 10 candidate genes 
 
PCR reactions were performed in the LightCycler 480 Real Time PCR instrument (Roche 
Diagnostics GmbH, Mannheim, Germany). The temperature profile of qPCR in this study 
was as follows: initial denaturation step for 5 min at 95°C, followed by 45 amplification 
cycles for 20 s at 95°C, 20 s at 60°C, and 20 s at 72°C.  
 
Output results were first preprocessed with the LightCycler® 480 Software (Figure 3). All 
samples with crossing point (Cp) cycle values higher than 35 were excluded from data 
collection. After preprocessing, all valid data was saved as text files for further statistical 
analyses. Saved data included fluorescence measurements at each cycle and Cp values. 
Data were imported into Excel software. 
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4.6 Statistical analysis 
 
The calculation of mRNA abundance was based on delta cycle threshold (△Ct) values. The 
method of Livak and Schmittgen (2001), so called 2-ΔΔCt method, was used in analyses of 
relative gene expression data. LinRegPCR (2004) software was used to calculate PCR 
efficiency corrected Ct values (Ramakers et al. 2002, Ruijter et al. 2009). Then, the Cq 
values were the PCR efficiency corrected Ct values. In addition, PCR efficiencies (Eff) 
were calculated with LinRegPCR software for all primer pairs.  
 
Relative mRNA abundance of genes between NG and CG groups in different SAT groups 
and between SAT groups were presented as 14-ΔCq values. Cq values were also used in 
gene expression fold change (2-ΔΔCt) analyses when target group were compared to 
control group.  
 
Figure 3. Snapshot of results output sheet from the LightCycler® 480 Software. 
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Figure 6. Snapshot of Shapiro Wilk normality test from R statistical software package. 
Figure 7. Plot distribution of ΔCt data from Shapiro Wilk normality test. 
 
Figure 9. Snapshot of Wilcoxon Rank Sum test from R statistical software package. 
The mean Cq values of both internal control genes and candidate genes were calculated as 
averages of replicates. The geometric mean of the three internal control genes (Cq.ICG.) was 
used to calculate mRNA abundance of candidate genes by accessing the relatively 
difference between their Ct values (ΔCq). ΔCq value was determined by equation:  
 
ΔCq= Cq.candidate – Cq.ICG  
 
The fold change in expression of the candidate gene relative to the internal control gene 
between groups was studied using 2-ΔΔCt method. For the samples in control group, ΔΔCq 
equals zero and 2-ΔΔCt was one. The fold change was calculated by equation:     
 
ΔΔCq= (Cq.candidate – Cq.ICG )Target – (Cq.candidate – Cq.ICG )control.  
 
Final statistical analyses were conducted using R statistical software package 
(http://www.r-project.org/). Distribution of variables was analyzed using the Shapiro Wilk 
normality test with histogram and Q-Q plot. The Wilcoxon rank sum test was used to 
analyse gene expression differences between different pasture groups and tissue groups.  
 
 
5 RESULTS 
 
5.1 Stability of internal control genes  
 
ACTB, GUSE and MRPL39 were selected as internal control genes ((ICG) in this study 
according to the stability validation conducted using NormFinder software (Table 3). The 
mRNA abundances of these three genes were stable between groups and different adipose 
tissues compared to candidate genes and thus, neither energy feeding or SAT tissue type 
does not affect their expression. 
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Table 3. Output results of gene stability from NormFinder. The lower the stability value, the more 
stable is the expression of the studied gene. 
 
Gene name Stability value 
ACTB 0.015 
GUSB 0.019 
MRPL39 0.011 
MTOR 0.033 
SREBF1 0.030 
SREBF2 0.025 
TBC 0.009 
INSR 0.028 
 
 
 
5.2 Total RNA quality 
 
The average RIN value of prepared total RNA samples was 7.7, average RNA 
concentration was 99.1 ng/ µl. Electropherograms for all samples of neck SAT (Figure 4) 
and tailhead SAT (Figure 5) reveal acceptable and rather uniform quality among all total 
RNA samples. 
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5.3 Gene expression between treatment groups 
 
There were no obvious gene expression differences between NG and CG groups in both 
neck and tailhead SAT based on fold changes (Figure 6). All candidate genes except TSC2 
had slightly higher expression in CG group than in NG group in neck SAT when using 
Wilcoxon rank sum test (Table 4). However, the differences were not obvious (p˃0.05), 
only RBP4 had significantly higher gene expression (p˂0.05) (Table 4).  
CG group showed lower mRNA abundance in tailhead SAT except TSC1 and TSC2 (Table 
5). The difference of TSC1 between NG and CG group in tailhead SAT was obvious 
(p˂0.05). 
 
Table 4. Relative mRNA abundances (14-ΔCq value) of genes between NG and CG groups in neck 
SAT and statistical significances of differences between groups based on Wilcoxon rank sum test. 
 
 NG SEM CG SEM P-value 
MTOR 11.49 0.81 11.85 0.53 0.418 
SREBF1   9.89 0.42 10.78 0.44 0.203 
SREBF2 12.47 0.55 12.51 0.56 0.817 
TBC1D7 10.61 0.13 11.04 0.34 0.475 
LEP 11.75 0.64 12.96 0.66 0.482  
GLUT4   9.05 0.41 10.33 0.44 0.064 
MCP1   7.86 0.40   8.93 0.60 0.225 
RBP4   9.09 0.44 11.57 0.89 0.035 
TSC1 11.60 0.12 11.65 0.23 0.488 
TSC2   7.34 0.49   7.07 0.50 0.643 
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Table 5. Relative mRNA abundances (14-ΔCq value) of genes between NG and CG groups in 
tailhead SAT and statistical significances of differences between groups based on Wilcoxon rank 
sum test. 
 
 NG SEM CG SEM P-value 
MTOR 10.64 0.42 10.51 0.74 0.910 
SREBF1 11.62 0.48 11.61 0.39 1.000 
SREBF2 11.80 0.37 11.50 0.67 0.817 
TBC1D7 11.15 0.27 10.23 0.47 0.133 
LEP 13.51 0.58 13.28 0.36 0.848 
GLUT4 10.42 0.31 11.24 0.63 0.302 
MCP1   8.31 0.49   8.05 0.59 0.796 
RBP4   9.30 0.78   8.23 0.29 0.475 
TSC1 11.41 0.10 11.74 0.16 0.071 
TSC2   7.28 0.55   7.52 0.69 0.699 
 
Figure 6. Fold change in gene expression (2-ΔΔC) of CG group using NG group as covariates in both 
Neck and Tailhead SAT (gene expression in NG group = 1).  
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5.4 Gene expression between neck and tailhead subcutaneous adipose tissue 
 
Two candidate genes had statistically significant differences in the gene expression 
between neck and tailhead SAT groups (Table 6). SREBF1 and GLUT4 had significantly 
higher expression (p˂0.05), and RBP4 had a trend of higher expression in tailhead adipose 
tissue (p˂0.10).  MTOR, SREBF2, TBC1D7, LEP, TSC1, TSC2 and MCP1 had 
approximately same expression levels between different SAT groups.  
 
Table 6. Relative mRNA abundances (14-ΔCq value) of genes between neck and tailhead SAT 
group and statistical significances of differences between groups based on Wilcoxon rank sum test. 
 
Genes 
14-ΔCq 
(Neck) SEM 
14-ΔCq 
(Tailhead) SEM P-value 
MTOR 11.66 0.48 10.58 0.39 0.191 
SREBF1 10.31 0.32 11.61 0.30 0.007 
SREBF2 12.49 0.38 11.66 0.36 0.206 
TBC1D7 10.81 0.17 10.72 0.28 0.765 
LEP 12.35 0.47 13.39 0.33 0.183 
GLUT4   9.65 0.34 10.77 0.33 0.026 
MCP1   8.39 0.38   8.20 0.36 0.927 
RBP4 10.33 0.59   8.81 0.45 0.066 
TSC1 11.62 0.12 11.55 0.09 0.359 
TSC2   7.22 0.34   7.38 0.42 0.760 
 
 
Relative mRNA fold change (determined by 2-ΔΔC) values between neck and tailhead group 
are presented in Figure 7. The neck group was referred as control group (gene expression 
=1) and then expression levels in tailhead group were compared to expression levels in 
control group (Figure 7). The fold change values of MTOR, SREBF2, TBC1D7, RBP4, 
TSC1 and TSC2 were around 1.00, which demonstrates that gene expression levels were 
about the same between different SAT groups. Although SREBF1, LEP, GLUT4 and MCP1 
had relatively high expression with fold change values 2.63, 2.10, 2.33, and 2.18 
respectively, the differences between SAT groups were not statistically significant. 
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Figure 7. Fold change in gene expression (2-ΔΔC) in tailhead SAT compared to neck SAT (neck gene expression = 1). 
 
 
6 Discussions 
 
6.1 Testing and validation of internal control genes 
 
For gene expression profiling of small number of genes the qPCR is an accurate and 
sensitive method. The method requires data normalization to account for analytical errors 
that introduce variation to measurements (Dheda et al. 2005, Valasek & Repa 2005). Data 
normalization can be done by using reference genes or ICGs (Dheda et al. 2005). Therefore, 
introducing ICG is the most reliable approach in qPCR analysis (Bionaz & Loor 2007). The 
expression of ICG should not associate with experimental treatment, or vary between 
investigated tissues (Vandesompele et al. 2002). It has been claimed that careful evaluation 
and validation of is standard requirement when working with qPCR technology (Bustin et 
al. 2009). 
 
27 
 
 
 
In this study, primers for six ICG genes were designed in the first place. However, 
according to the desired length of product and the nearest neighbor temperatures, only 
expression of ACTB, GUSB and MRPL39 were tested together with candidate genes. The 
expression stabilities of the selected ICG were evaluated through treatment groups and 
adipose tissues with NormFinder software (Andersen et al. 2004). Finally, the geometric 
mean of the three internal control genes was used in the statistical analyses in this study. 
 
6.2 mRNA expressions between CG and NG group 
 
In this study, RBP4 had significantly higher and GLUT4 had a trend to higher mRNA 
expression levels in CG group than at NG group in neck SAT. While, only TSC1 had trend 
to higher expression in CG group at tailhead SAT. Gene expression of SREBF1, SREBF2, 
TBE1D7, TSC2 at both neck and tailhead SAT were not different between treatment groups. 
RBP4 is an adipokine that contributes to insulin resistance in obesity and type-2 diabetes 
(Yang et al. 2005, Graham et al. 2006). In the mouse model, serum RBP4 levels in obesity 
and insulin resistance groups were significantly higher than in the control group, and the 
GLUT4 gene knockout mice had obviously higher insulin sensitivity than the wild-type 
control group mice (Yang et al. 2005). Expression of GLUT4 was reported down-regulated 
selectively in adipocyte and not in skeletal muscle in insulin-resistant states (Shepherd & 
Kahn 1999). Down-regulation of GLUT4 can cause insulin resistance and increase the risk 
of developing diabetes (Abel, et al. 2001). Increased serum levels of RBP4 have been 
detected in adipose-specific GLUT4 knockout (adipose-GLUT4 -/-) mice (Yang et al. 
2005). 
 
Thus, in mice adipose tissue, RBP4 expression was inversely correlated with GLUT4 
expression because adipocytes sense glucose uptake and regulate systemic glucose 
metabolism through RBP4. However, in equine adipocyte studies, no statistical differences 
were detected in mRNA expression of RBP4 between insulin resistant and insulin sensitive 
groups of ponies in tailhead SAT (Ungru et al. 2012). RBP4 expression levels closely 
linked with adiposity, but they were independent of other obesity factors such as insulin 
sensitivity (Ungru et al. 2012). 
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It was claimed that RBP4 might be regulated differently in mice and humans (Janke et al. 
2006). In human subjects, a positive correlation was found between RBP4 and GLUT4 
expression levels (Janke et al. 2006). Increased serum RBP4 levels were observed in 
humans with in insulin-resistant states such as obesity, type-2 diabetes (Graham et al. 2006). 
In adipose tissue, GLUT4 expression was the only determinate factor of RBP4 expression.  
 
These results may indicate that regulation and expression of RBP4 in horse adipose tissue 
may be more similar with expression in adipose in human than in mice. It should be noted 
that subjects of this study were mature Finnhorses while Ungru et al (2012) studied ponies. 
Comparing results of this study and Ungru et al. 2012, it is assumed that the function of 
adipokines in metabolism may be different in ponies and horses, which is of interests for 
further study.  
 
LEP serves as an important endocrine signal of nutritional status and adipose tissue mass in 
the horse (Houseknecht et al. 1998). It regulates appetite, homeostasis and adipogenesis 
(Ingvartsen & Boisclair 2001). In horses, studies have reported that the plasma LEP 
concentration was positively correlated with adipose tissue mass (Buff et al. 2002, Kearns 
et al. 2006). Other study has indicated a strong correlation between LEP concentration and 
degree of insulin resistance (Van Weyanberg et al. 2007).  
 
In my study, the relatively higher expression of LEP in CG group may indicate greater fat 
mass due to overfeeding, which associates with risk of obesity or insulin resistance. This 
result agreed with the recent study that reported up-regulation of LEP expression in overfed 
dairy cow (Ji et al. 2014). However, the mRNA expression of LEP had no statistically 
significant difference between CG and NG mares in either neck or tailhead SAT.   
 
MCP1 is a type of inflammatory cytokine with chemotactic function which might be related 
to the monocytes associated inflammatory process (Kanda et al. 2006). Obesity is 
associated with macrophage accumulation in adipose tissue (Weisberg et al. 2003). MCP1 
contributes to macrophage infiltration into adipose tissue and insulin resistance in obesity 
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(Kanda et al. 2006). In obese human subjects, the mRNA expression of MCP1 was up-
regulated in adipose tissue, which was correlated directly with adiposity (Christiansen et al. 
2005). Increased circulating levels of MCP1 were observed in obese humans and they 
associated with body mass index (Kim et al. 2006). MCP1 levels were higher in diabetic 
than in non-diabetic Afro-Caribbean subjects (Ezenwaka et al. 2009). Tateya et al (2010) 
also reported that elevated circulating concentration of MCP1 caused systemic insulin 
resistance in mice.  
 
However, only a trend of higher mRNA expression of MCP1 in CG group than in NG 
group was observed in this study, yet expression difference between treatment groups was 
not significant. A higher mRNA expression of MCP1 was detected in CG group compared 
to NG group in tailhead SAT (Selim et al. 2013). It has been reported that there were no 
statistically significant differences in mRNA expression of anti-inflammatory 
adipocytokine such as MCP1 between insulin resistant and insulin sensitive groups from 
visceral and various SAT in obese horses (Burns et al. 2010).   
 
These findings may suggest that the mares might have to undergo a prolonged period of 
energy feeding to get greater fat reserves and obesity levels, before the up-regulation of 
MCP-1 or LEP in SAT will be detectable. Alternatively, grazing on high yielding pasture 
may not cause risk of metabolic diseases that associated with mTOR1 pathway regulation 
when the horses were with healthy body condition score before the grazing season.  
 
Besides, the Finnhorses in this study were grazed in quite high latitude (60.795ºN and 
23.315 ºE). Finnhorse mares’ hormone secretion, e.g. alpha-melanocyte stimulating 
hormone (alpha-MSH) and metabolism activity may have been adapted to accumulation of 
adipose tissue during the grazing season (Ⅲ), in order to adapt to the winter season. 
Hoggard et al. (2004) claimed that increased alpha-MSH inhibited LEP gene expression. It 
is also suggested that even higher or prolonged energy feeding period would be needed for 
the onset insulin-resistant states and this kind of experiment could be interesting for further 
study.  
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6.3 mRNA expressions between neck and tailhead SAT 
 
In equidae, adipose tissue distributed especially on the crest of the neck might contribute to 
hyperinsulinemia, insulin resistance and/or an increased risk of laminitis (Carter et al. 2009, 
Frank et al. 2010b). Interestingly, selected mRNA expression profile in nuchal ligament 
SAT was found more active than other fat depots including tailhead SAT (Burns et al. 
2010). Neck SAT was claimed to have outstanding and unique role in horse adipobiology 
processes and in metabolism related diseases such as equine metabolic syndrome (Burns et 
al. 2010).  
 
It has been shown in horses that expression differences of glucose transporters were 
associated to different adipose tissues (Waller et al. 2011). Total GLUT4 expression was 
significantly greater in visceral adipose tissue compared to SAT in both insulin sensitive 
and resistant groups (Waller et al. 2011). In this study, significantly higher expression of 
GLUT4 was found in tailhead SAT compared to neck SAT (P<0.05).  
 
LEP mRNA expression was found to be significantly higher in neck than in mesenteric 
SAT samples that were collected from different breeds, ages and varying body condition 
(Lien et al. 2013). Since previous study has indicated a strong correlation between LEP 
concentration and degree of insulin resistance (Van Weyanberg et al. 2007), it was assumed 
that enlarged nuchal adipose tissue could be a key risk factor for metabolic diseases (Carter 
et al. 2009, Frank et al. 2010b). However, higher but not significant expression of LEP was 
observed in tailhead SAT (0.61) compared to neck SAT (1.65) in this study. 
 
The unexpectedly higher expression of SREBF1, GLUT4 and LEP in tailhead may indicate 
that tailhead SAT accumulated more fatness than neck SAT after the grazing season. A 
previous study by Särkijärvi et al (2012) reported that the differences of fat deposition in 
neck area were small, despite that CG group had more fatness during grazing season. 
However, in tailhead adipose, the fat thickness was significantly different between groups 
in the end of grazing season (Särkijärvi et al. 2012). The mRNA expression of SREBF1, 
GLUT4 and LEP may be upregulated in response to the significantly greater fat 
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accumulation in tailhead SAT. In contrast, the fatness difference in neck SAT may not be 
great enough to affect the mRNA expression of studied genes. 
 
A trend of higher mRNA expression of RBP4 was shown in neck SAT compared to 
tailhead SAT (P<0.10). It may indicate different roles of neck and tailhead SAT in 
regulation of metabolism, which is of interests to compare expression from different 
adipose tissue locations in further studies. No significant mRNA expression differences 
were observed in MTOR, SREBF2, TBC1D7, TSC1 and TSC2 genes between neck and 
tailhead SAT. The result is in line with a previous study that no differences were detected 
in pro-inflammatory cytokines and adipokines in mRNA expression between insulin 
resistant and insulin sensitive horses (Burns et al. 2010). 
 
6.4 Hypotheses about mTORC1 pathway genes 
 
Our hypotheses were that mares in CG would have increased fat deposition in SAT 
including neck and tailhead area, which might lead to higher mRNA expression in insulin 
and mTORC1 pathway genes. However, Särkijärvi et al. (2012) claimed no statistical 
differences between NG and CG in neck SAT before and after grazing. In May, there were 
no significant body weight differences between groups, while CG group had significantly 
higher body weight after grazing in September (Särkijärvi et al. 2012). It may indicate that 
although the body weight significantly increased due to high energy feeding in CG during 
the grazing season, the fat deposition in neck SAT was not affected enough to upregulate 
expression of mTORC1 pathway genes. In tailhead SAT, CG mares had smaller fat 
thickness in May and this difference disappeared in September (Särkijärvi et al. 2012). It 
may explain that no mRNA expression differences in tailhead SAT were detected between 
groups.  
 
In addition, Selim et al. (2015) presented that no differences were detected in plasma 
glucose and basal NEFA levels between CG and NG groups. Similarly, it has been reported 
that high energy feeding over 16 weeks had no effect on plasma NEFA concentrations 
despite it induced obesity in horses (Carter et al. 2009). However, increased plasma NEFA 
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concentration was reported in obese horses due to insulin resistance (Frank et al. 2006). It is 
suggested that mares in CG group may need prolonged feeding period or higher energy 
feeding difference between groups before distinct differences can be detected in expression 
levels of studied mTORC1 genes in adipose tissues.   
 
 
7 CONCLUSIONS 
 
The lack of distinct expression differences between groups may indicate that pasture 
associated fat deposition may not considerably affect expression of insulin pathway and 
mTORC1 genes in neck and tailhead adipose tissue in Finnhorse mares. These results also 
provide additional evidence to our hypothesis that fattening resulting on unrestricted 
grazing on cultivated high-yielding pasture does not increase the risk of metabolic diseases 
in Finnhorse mares when they have normal body condition at the beginning of the grazing 
season. 
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